Full history for every metric is available with a Kvantra account
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 41 | 1,078 | 411 | 1,226 | 2,190 | 4,153 | 6,021 | 6,194 |
| Operating profit | $m | 1,055 | 1,698 | ||||||
| Net profit | $m | -608 | -408 | -710 | -295 | 833 | 1,292 | 1,886 | 1,934 |
| EPS reported | $ | 19.63 | 26.24 | ||||||
| Operating cashflow per share | $ | 13.88 | 18.05 | ||||||
| Capex per share | $ | 0.10 | 0.06 | ||||||
| FCF per share | $ | 13.77 | 18.00 | ||||||
| Free cash flow | $m | 844 | 1,156 | ||||||
| Net debt | $m | -4,393 | -5,184 | ||||||
| Book value equity | $m | 7,323 | 8,417 | ||||||
| Book value per share | $ | 110.9 | 130.7 | ||||||
| Number of shares | m | 66.03 | 64.41 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 42.84 | - | ||||||
| P/B LTM | x | 7.04 | 6.79 | ||||||
| P/S LTM | x | 12.41 | 9.49 | ||||||
| P/FCF LTM | x | 61.05 | 49.47 | ||||||
| EV/EBITDA LTM | x | 36.72 | 27.75 | ||||||
| EV/Sales LTM | x | 11.59 | 8.63 | ||||||
| Earnings Yield LTM | % | 2.33% | 2.99% | ||||||
| FCF Yield | % | 1.64% | 2.02% | ||||||
| Quality | |||||||||
| ROE | % | 17.64% | 21.66% | ||||||
| ROIC | % | 14.30% | 17.36% | ||||||
| Operating margin | % | 25.39% | 28.81% | ||||||
| Gross margin | % | 89.15% | 89.94% | ||||||
| FCF/Sales | % | 20.33% | 21.58% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +53.60% | +16.42% | ||||||
| Sales Growth YoY | % | +89.64% | +64.60% | ||||||
| Net Income Growth YoY | % | +55.10% | +37.45% | ||||||
| FCF Growth | % | - | +232.02% | ||||||
| Operating Profit Growth | % | - | +260.11% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | 0.00% | 0.00% | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 10.11 | 24.59 | ||||||
| Net Debt/EBITDA | x | -2.60 | -2.23 | ||||||
| EBIT/Net interest | x | 258.36 | 393.80 | ||||||
| Net debt/market cap | % | -8.52% | -9.07% | ||||||
| Net debt/Equity | x | -0.60 | -0.62 | ||||||
| Gross debt/equity | x | 0.01 | 0.01 | ||||||
ETFs that hold argenx
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| iShares Biotechnology ETF | IBB | 7 | 3.79% |
| iShares MSCI Europe Health Care Sector UCITS ETF | ESIH.DE | 7 | 3.39% |
| iShares STOXX Europe 600 Health Care UCITS ETF (DE) | EXV4.DE | 7 | 3.25% |
| State Street SPDR MSCI Europe Health Care UCITS ETF | HLTH.L | 7 | 3.43% |
| Dynamic Active Global Dividend ETF | DXG.TO | 5 | 4.49% |
| VanEck Biotech ETF | BBH | 7 | 4.62% |
| Xtrackers MSCI Europe Health Care Screened UCITS ETF 1C | DXSE.DE | 7 | 3.45% |
| iShares MSCI Belgium ETF | EWK | 2 | 16.79% |
| Ossiam Shiller Barclays Cape Europe Sector Value TR | CAPE.PA | 7 | 4.26% |
| VanEck European Equal Weight Screened UCITS ETF | TEET.AS | 6 | 1.31% |
Funds with argenx among their ten largest holdings, largest fund first.
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
argenx SE, a biotechnology company established in Amsterdam, the Netherlands, in 2008, is dedicated to developing innovative therapies primarily for autoimmune diseases. The company's operations span across key global markets, including the United States, Japan, Europe, the Middle East, Africa, and China. Its leading investigational therapy is efgartigimod, which is being developed to address a broad range of conditions. These include generalized myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary Sjögren's syndrome, post-COVID postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, ANCA-associated vasculitis, and antibody-mediated rejection. Also noted in connection with its lead product efforts is ENHANZE SC. The company's extensive development pipeline features several other promising candidates. Empasiprubart is in development for multifocal motor neuropathy, delayed graft function, and dermatomyositis. ARGX-119 is being investigated for congenital myasthenic syndrome and amyotrophic lateral sclerosis. Further pipeline assets include ARGX-213, which targets FcRn; ARGX-121 and ARGX-220, both designed to modulate the immune system; ARGX-109, which targets IL-6; and ARGX-118, developed for inflammatory indications. argenx is also advancing cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. The company’s portfolio encompasses several proprietary products and brands, such as VYVGART, VYVGART HYTRULO, VYVDURA, ARGENX, ABDEG, NHANCE, SIMPLE ANTIBODY, and ARGENXMEDHUB. Strategic collaborations are integral to argenx's business model. It maintains partnerships with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S, alongside numerous collaboration and license agreements with entities including Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. A specific collaboration with Genmab A/S focuses on the discovery, development, and commercialization of novel therapeutic antibodies for immunology and oncology applications. Additionally, argenx has a strategic collaboration with IQVIA Holdings Inc. for the provision of safety systems and related services.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| iShares Biotechnology ETF | IBB | 7 | 3.79% |
| iShares MSCI Europe Health Care Sector UCITS ETF | ESIH.DE | 7 | 3.39% |
| iShares STOXX Europe 600 Health Care UCITS ETF (DE) | EXV4.DE | 7 | 3.25% |
| State Street SPDR MSCI Europe Health Care UCITS ETF | HLTH.L | 7 | 3.43% |
| Dynamic Active Global Dividend ETF | DXG.TO | 5 | 4.49% |
| VanEck Biotech ETF | BBH | 7 | 4.62% |
| Xtrackers MSCI Europe Health Care Screened UCITS ETF 1C | DXSE.DE | 7 | 3.45% |
| iShares MSCI Belgium ETF | EWK | 2 | 16.79% |
| Ossiam Shiller Barclays Cape Europe Sector Value TR | CAPE.PA | 7 | 4.26% |
| VanEck European Equal Weight Screened UCITS ETF | TEET.AS | 6 | 1.31% |
Funds with argenx among their ten largest holdings, largest fund first.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
argenx SE, a biotechnology company established in Amsterdam, the Netherlands, in 2008, is dedicated to developing innovative therapies primarily for autoimmune diseases. The company's operations span across key global markets, including the United States, Japan, Europe, the Middle East, Africa, and China. Its leading investigational therapy is efgartigimod, which is being developed to address a broad range of conditions. These include generalized myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary Sjögren's syndrome, post-COVID postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, ANCA-associated vasculitis, and antibody-mediated rejection. Also noted in connection with its lead product efforts is ENHANZE SC. The company's extensive development pipeline features several other promising candidates. Empasiprubart is in development for multifocal motor neuropathy, delayed graft function, and dermatomyositis. ARGX-119 is being investigated for congenital myasthenic syndrome and amyotrophic lateral sclerosis. Further pipeline assets include ARGX-213, which targets FcRn; ARGX-121 and ARGX-220, both designed to modulate the immune system; ARGX-109, which targets IL-6; and ARGX-118, developed for inflammatory indications. argenx is also advancing cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. The company’s portfolio encompasses several proprietary products and brands, such as VYVGART, VYVGART HYTRULO, VYVDURA, ARGENX, ABDEG, NHANCE, SIMPLE ANTIBODY, and ARGENXMEDHUB. Strategic collaborations are integral to argenx's business model. It maintains partnerships with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S, alongside numerous collaboration and license agreements with entities including Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. A specific collaboration with Genmab A/S focuses on the discovery, development, and commercialization of novel therapeutic antibodies for immunology and oncology applications. Additionally, argenx has a strategic collaboration with IQVIA Holdings Inc. for the provision of safety systems and related services.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free